Novo Nordisk A/S (NOVOb.CO)
995.00DKK
17 May 2013
kr.-3.00 (-0.30%)
kr.998.00
kr.998.50
kr.1,006.00
kr.990.50
572,147
715,288
kr.1,100.00
kr.770.00
NOVOb.CO
About
Overall
| Beta: | 0.46 |
| Market Cap (Mil.): | kr.440,300.31 |
| Shares Outstanding (Mil.): | 442.51 |
| Dividend: | 18.00 |
| Yield (%): | 1.81 |
Financials
| NOVOb.CO | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 23.95 | 34.17 | 34.44 |
| EPS (TTM): | 41.55 | -- | -- |
| ROI: | 59.84 | 19.17 | 18.54 |
| ROE: | 68.77 | 19.90 | 19.38 |
Novo Nordisk says completes hemophilia drug trial
COPENHAGEN - Denmark's Novo Nordisk, the world's biggest insulin producer, said on Friday it had completed the first phase III trial of a hemophilia drug, N9-GP.
UPDATE 3-NORDIC STOCKS - Factors to watch on May 17
(Adds Sanoma, Volvo, updates A.P. Moller-Maersk, FLSmidth)
Europe must pay up for new drugs: Novo Nordisk CEO
NEW YORK - Europe must start paying more for new medicines and take some of the cost burden of supporting pharmaceutical drug development off the United States, Novo Nordisk's Chief Executive Lars Sorensen said.
Novo's long-term targets hinge on two drugs: CEO
NEW YORK - Novo Nordisk's long-term profit targets are hanging in the balance after a big setback in the U.S. market but the Danish drugmaker may yet hit its goal if things work out for one of two drugs, its CEO said.
Sanofi says to step up development of new diabetes device
PARIS, May 2 - Sanofi is stepping up the development of a fixed combination of diabetes treatments Lantus and Lyxumia to sidestep an earlier setback with a similar pen device and take advantage of the delayed U.S. launch of competitor Novo Nordisk's new insulin.
U.S. launch of Novo's new insulin faces long delay
COPENHAGEN - Denmark's Novo Nordisk could see the U.S. launch of its biggest drug hope, a new long-acting insulin, delayed until 2018 while it conducts more tests to satisfy regulators, it said on Wednesday.
UPDATE 2-U.S. launch of Novo's new insulin faces long delay
COPENHAGEN, May 1 - Denmark's Novo Nordisk could see the U.S. launch of its biggest drug hope, a new long-acting insulin, delayed until 2018 while it conducts more tests to satisfy regulators, it said on Wednesday.
NOVO NORDISK A/S : NOVO NORDISK A/S INCREASED OPERATING PROFIT BY 18% IN THE FIRST QUARTER OF 2013
COPENHAGEN, May 1 - Denmark's Novo Nordisk , the world's biggest insulin producer, slightly raised its sales growth outlook for the full year after first quarter operating profit rose more than forecasts.
BRIEF-Novo Nordisk owns 1.9% of its share capital
COPENHAGEN, April 22 - Novo Nordisk A/S : * Says owns a total of 1.9% of its share capital * Says has as of 19 April repurchased a total of 2.8 million B-shares with
Diabetes, bone, pain drugs may face German price cuts
FRANKFURT, April 18 - Drugs from Novo Nordisk , Amgen, Bayer and other companies could face price cuts in Germany as the country's medical cost-benefit agency widens a review into the value offered by medicines.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Thomson Reuters StreetEvents
|
$75.00
|
|
Provider: Thomson Reuters StreetEvents
|
$75.00
|
|
Provider: Thomson Reuters StreetEvents
|
$75.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
